On 2026年5月9日, the U.S. Food and Drug Administration (FDA) issued the "Digital Health Device Website Transparency Guidance," requiring Chinese suppliers of Class II and higher medical devices sold to the U.S. market to prominently disclose on their English standalone website product pages the source country of clinical validation data, the name of the original trial institution, and the composition of AI-assisted diagnostic model training datasets (including data regions, sample size, and de-identification methods). This requirement will be mandatorily enforced starting from 2026年8月1日, directly affecting the technical credibility assessment and compliance readiness timeline of medical device exporters, with clear practical implications for segmented fields such as digital health, AI medical devices, and cross-border medical device trade.

Event Overview

On 2026年5月9日, the U.S. Food and Drug Administration (FDA) officially released the "Digital Health Device Website Transparency Guidance" ("数字健康设备网站透明度指南"). The guidance makes it clear that all Chinese manufacturers selling Class II and higher medical devices in the U.S. market, if conducting product promotion or sales through their own English standalone websites, must publicly display in a prominent position on the corresponding product pages three core pieces of information — the source country of clinical validation data, the full name of the institution conducting the original clinical trial, and the composition of the training dataset for any integrated AI-assisted diagnostic model, specifically including the geographic source of the training data, the total sample size, and the data de-identification method used. This requirement will officially take effect on 2026年8月1日 and be included within the scope of compliance review.

Which Segmented Industries Will Be Affected

Direct Trade Enterprises

Such companies typically supply U.S. distributors, medical institutions, or DTC platforms under their own brands or in an ODM model, and operate English standalone websites targeting overseas users. Because the guidance directly governs standalone website content of "Chinese suppliers of Class II and higher medical devices sold to the U.S. market," the compliance of their product pages will directly affect downstream procurement decisions. The impact is mainly reflected in lower response efficiency to customer due diligence, longer contract signing cycles, and reduced webpage traffic conversion rates caused by incomplete information disclosure.

Processing and Manufacturing Enterprises (including certified production enterprises)

As the registered entity actually holding FDA 510(k) or De Novo clearance, the manufacturing enterprise must bear ultimate compliance responsibility for official website disclosures, even if the website is operated on behalf of the brand owner or channel partner. The impact is concentrated in increased pressure for internal cross-department coordination — the clinical department must provide traceable proof of trial institutions and data sources, the AI algorithm team must produce structured training dataset metadata, and the legal and regulatory affairs departments must jointly review the boundaries of wording. Enterprises that have not established a data traceability documentation system will face the risk that disclosure content cannot be effectively implemented.

Channel Distribution Enterprises (including U.S. local distributors and importers)

Under current FDA regulations, importers within the United States (U.S. Agent / Importer of Record) have supervisory obligations regarding the compliance status of the products they represent. Although the new guidance does not directly bind their websites, if a distributor's official website embeds links to manufacturer product pages or reuses their content, it may also be regarded as "participating in product information presentation." The impact is reflected in the increased weighting of evaluating upstream suppliers' disclosure capabilities, and some distributors have already begun including "standalone website transparency readiness" in their new partner onboarding checklists.

Key Points Relevant Enterprises or Practitioners Should Watch, and How to Respond at Present

Prioritize Reviewing the Current Disclosure Status of Existing English Standalone Website Product Pages

Verify item by item against the original guidance text: whether fixed modules have already been set on Class II and higher product pages, clearly indicating the country where the clinical trial was conducted, the full name of the CRO or hospital (not an abbreviation), the countries/regions covered by AI training data, the total sample size value (not a range), and the de-identification method (such as standard terminology like k-anonymity or differential privacy). Avoid using vague expressions such as "multi-center" or "collected across multiple countries globally."

Differentiate Policy Signals from Business Implementation Milestones

The guidance is a "guidance document" (Guidance), not a regulation (Regulation), but the FDA has clearly stated that website disclosures will be included as a focus area in postmarket surveillance and inspections. What deserves more attention at present is this: after 2026年8月1日, if a newly submitted 510(k) application includes a standalone website link, FDA reviewers may proactively check the completeness of disclosures; if existing products are selected for random inspection, this may also trigger a corrective action notice.

Synchronously Update SEO Metadata and Structured Data

Schema.org markup (such as MedicalDevice and ClinicalTrial) needs to be added to the product page HTML to ensure that fields such as "funding," "studyLocation," and "datasetSize" can be recognized by search engines; the page title (Title Tag) and description (Meta Description) should naturally incorporate English long-tail keywords such as "clinical data source" and "AI training dataset," balancing compliance disclosure and search visibility while avoiding fluctuations in historical rankings caused by page revisions.

Establish a Cross-Functional Disclosure Collaboration Mechanism

It is recommended that the regulatory affairs department take the lead, working together with clinical affairs, AI algorithms, legal, and digital marketing teams to form a quarterly update mechanism: key nodes such as changes in clinical trial institutions, AI model iteration upgrades, and data compliance audit results must simultaneously trigger the website disclosure content revision process, and version records and approval trails should be retained for potential regulatory inquiries.

Editorial Viewpoint / Industry Observation

Observably, this guidance is not a standalone regulatory shift but a formalization of an emerging FDA expectation — transparency as infrastructure for digital health trust. It signals that website content is now treated as part of the device’s technical documentation ecosystem, rather than mere marketing material. Analysis shows the emphasis lies less on punitive enforcement and more on enabling downstream stakeholders (distributors, clinicians, payers) to assess evidence maturity at first touch. From industry perspective, it reflects a broader trend: regulatory agencies increasingly treating publicly accessible digital assets as extension points of compliance, especially where AI and real-world data are involved. The requirement is currently operational — not hypothetical — and its enforcement threshold appears tied to verifiability, not volume.

Conclusion: this guidance does not create an entirely new compliance obligation, but rather extends existing clinical and AI data governance requirements to the public-facing digital interfaces of enterprises. Its core significance lies in pushing "verifiability" from internal regulatory documentation to information touchpoints accessible in international markets. At present, it is more appropriate to understand it as a systematic stress test of the compliance maturity of medical device companies' digital assets, rather than a simple content update task.

Information source note:
Main source: the "Digital Health Device Website Transparency Guidance" published on the official website of the U.S. Food and Drug Administration (FDA), with a publication date of 2026年5月9日.
Items requiring continued observation: whether the FDA will subsequently issue FAQs or sample templates regarding the specific presentation forms of "prominent position" and "training dataset composition"; whether state-level healthcare procurement parties will incorporate this disclosure requirement into supplier access evaluation indicators.